Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
55
NCT00572637
Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2007
Completion: Mar 31, 2010